FSD Pharma Inc. is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative and inflammatory disorders. The three licensed drug candidates are LUCID-MS, a new chemical entity targeting Multiple Sclerosis, LUCID-PSYCH, a psychoactive molecule targeting Major Depressive Disorder, and FSD-PEA, an ultra-micronized Palmitoyl ethylamine with a favorable safety profile targeting inflammation.